phase readout
saveNCT06832618: A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
ACTIVE_NOT_RECRUITINGupdated 11d ago
community read0 votes
Sponsor: Incyte Corporation. Phase: PHASE3. Conditions: Atopic Dermatitis
view source ↗
comments(0)
5-min edit window · permanent after that